Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study

Speaker(s)

Kalia S1, Wiseman MC2, Loo WJ3, Brassard D4, Adam DN5, Kelly V6, Wong R7, Gaudet V8, Barbeau M8, Barakat M8, Eberg M9, Kalson-Ray S9
1University of British Columbia, Vancouver, BC, Canada, 2SKiNWISE Dermatology, Winnipeg, MB, Canada, 3DermEffects, London, ON, Canada, 4Clinique D, Laval, QC, Canada, 5University of Toronto, Toronto, ON, Canada, 6Clinique Médicale Saint-Louis, Quebec, QC, Canada, 7Rejuvenation Dermatology Clinic, Edmonton, AB, Canada, 8Bausch Health, Canada Inc., Laval, QC, Canada, 9IQVIA Inc., Kirkland, QC, Canada

Presentation Documents

OBJECTIVES: To describe the effectiveness, safety, and impact of brodalumab on the quality of life and work productivity of patients with plaque psoriasis (PsO). In this interim analysis, we describe the baseline and clinical characteristics of patients enrolled in the CARE study.

METHODS: CARE is a Canadian multi-center, 12-month prospective, observational study in adult patients with PsO who are initiating brodalumab as part of routine clinical care. Patient reported outcomes and physician assessments are collected prior to brodalumab initiation (baseline), and at 3-, 6-, and 12-months post-initiation.

RESULTS: At interim analysis, 166 patients (59.6% male, 78.9% Caucasian) with verified baseline data were included. The majority (83.1%) of patients were <65 years and the mean age was 51.0 (SD:13.2). Most were employed (73.1%; 106/145), reported a household income of ≤$100,000 (69.7%, 85/122), and had private (60.6%; 86/142) or public (28.2%; 40/142) insurance as primary medication coverage at the time of study enrolment.

Nearly two-thirds of patients (63.3%; 100/158) reported a disease duration ≥10 years. Amongst all 166 study patients, 92.2% had a history of prior PsO treatments but 84.3% were bio-naïve. Reported rates of special site involvement were scalp (69.3%), hands (56.6%), face (54.8%), feet (45.2%), and genitalia (31.3%). The majority (71.0%) reported at least one comorbidity of interest including hypertension (26.5%), psoriatic arthritis (17.5%), type 2 diabetes mellitus (13.9%), and depression (13.9%).

At baseline, disease severity using the Static Physician’s Global Assessment (sPGA) (n=166) was predominantly moderate (64.5%) and severe (31.3%), and mean Psoriasis Area and Severity Index (PASI) score (n=166) was 13.9 (SD:9.5). Patient reported mean Dermatology Life Quality Index (DLQI) score (n=145) was 14.0 (SD:7.4) and Psoriasis Symptom Inventory score (PSI) (n=160) was 18.7 (SD:7.1).

CONCLUSIONS: Patients participating in the CARE study had significant disease involvement and impairment of quality of life at baseline prior to the initiation of brodalumab.

Code

PCR258

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)